Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by
autoantibodies against the recently discovered podocyte antigens: the M-type …

Glomerulonephritis (GN) is an important cause of morbidity and mortality in patients of all
ages throughout the world. Because these disorders are relatively rare, it is difficult to …

Background B-cell anomalies play a role in the pathogenesis of membranous nephropathy.
B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine …

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been
conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals …

Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary
membranous nephropathy (MN), even after other treatments have failed. To assess the …

IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of
immunosuppressive agents added to standard therapy, several recent studies have …

Autoantibodies to the M-type phospholipase A 2 receptor (PLA 2 R) are sensitive and
specific for idiopathic membranous nephropathy. The anti-B cell agent rituximab is a …

Kidney biopsy is the gold standard to diagnose membranous nephropathy (MN).
Approximately 70%-80% of patients with primary MN have anti-phospholipase A2 receptor …

Results A total of 53 (78%) participants achieved complete peripheral depletion (0 cells/µl)
in a median time of 182 days (interquartile range, 80–339). The median duration of complete …

Selective depletion of B cells with the mAb rituximab may benefit the autoimmune
glomerular disease idiopathic membranous nephropathy (IMN). Here, we describe our …